Acumen Pharmaceuticals Inc.

ABOS | NASDAQ

Price Alert Chart Builder DCF Calculator

$2.59

-$0.06 (-2.26%)

At close: Sep 21, 2026, 4:00 PM ET

$2.60

+$0.01 (+0.39%)

Pre-market: Sep 22, 2026, 9:16 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $187.07M

Enterprise Value $108.44M

Beta 0.33

Average Volume 420.6K

Shares Outstanding (Diluted) 72.25M

Shares Change YoY 19.28%

Institutional Ownership 72.76%

Exchange NASDAQ

ISIN US00509G2093

Price Performance

Price Change 1M -18.3%

Price Change 3M 7.5%

Price Change 6M -1.5%

Price Change YTD 28.2%

Price Change 1Y 102.3%

Price Change 3Y -41.8%

Price Change 5Y -84.0%

1M CAGR (ann.) 6.2%

1Y CAGR (ann.) 96.2%

5Y CAGR (ann.) -30.6%

All-Time CAGR -32.4%

Valuation

PE Ratio -1.58

Forward PE N/A

PEG Ratio -0.05

Forward PEG 0.49

PS Ratio N/A

Forward PS N/A

PB Ratio 3.27

P/FCF Ratio -2.04

P/Adj. FCF Ratio -1.84

P/OCF Ratio -2.04

EV/Sales N/A

EV/EBIT -1.08

EV/EBITDA -1.08

EV/FCF -1.18

Earnings Yield -63.3%

FCF Yield -49.1%

Adj. FCF Yield -54.3%

Financial Health

Net Cash $78.63M

Total Debt $31.57M

Cash & Short-Term Investments $110.2M

Total Assets $116.01M

Current Ratio 2.47

Quick Ratio 2.47

Debt / Equity Ratio 0.55

Debt / EBITDA -0.31

Debt / FCF -0.34

OCF / Debt -2.91

Interest Coverage -24.41

Altman Z-Score -6.28

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin 0.0%

Operating Profit Margin 0.0%

EBITDA Margin 0.0%

Net Profit Margin 0.0%

FCF Margin N/A

Adj. FCF Margin N/A

SBC / Revenue 0.0%

SBC Impact (per share) -10.7%

Returns

Return on Assets -90.5%

Return on Equity -136.3%

Return on Invested Capital -118.6%

Return on Capital Employed -152.4%

Return on Tangible Assets -90.6%

Historical Growth (CAGR)

Revenue CAGR 3Y N/A

Revenue CAGR 5Y N/A

Revenue CAGR 10Y N/A

EPS CAGR 3Y -15.8%

EPS CAGR 5Y -21.0%

EPS CAGR 10Y N/A

FCF CAGR 3Y -20.4%

FCF CAGR 5Y -31.0%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 8

EPS Growth Next 3Y 18.5%

Revenue Growth Next 3Y N/A

Earnings Date Nov 10, 2026

EPS Estimate (next Q) -$0.43

EPS Growth Est (next Q) -2.3%

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $7

Price Target Upside 170.3%

Cash Flow

Operating Cash Flow $-91.79M

Free Cash Flow $-91.79M

Adj. Free Cash Flow $-101.59M

FCF Per Share -$1.27

OCF Per Share -$1.27

OCF/S Ratio 0.0%

Income Statement

Revenue $0

Gross Profit $-46K

Operating Income $-105.42M

EBITDA $-100.4M

Net Income $-105.04M

EPS (Diluted) -$1.64

Revenue / Employee N/A

Profit / Employee $-1.72M

Employees 61